Literature DB >> 25789701

IL-31 Induces Chemotaxis, Calcium Mobilization, Release of Reactive Oxygen Species, and CCL26 in Eosinophils, Which Are Capable to Release IL-31.

Nikola Kunsleben1, Urda Rüdrich1, Manuela Gehring1, Natalija Novak2, Alexander Kapp1, Ulrike Raap3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25789701     DOI： 10.1038/jid.2015.106

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  16 in total

Review 1.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

2.  Correlation of IL-31 serum levels with severity of atopic dermatitis.

Authors:  Ulrike Raap; Katja Wichmann; Manuela Bruder; Sonja Ständer; Bettina Wedi; Alexander Kapp; Thomas Werfel
Journal:  J Allergy Clin Immunol       Date:  2008-08       Impact factor: 10.793

Review 3.  Signaling by IL-31 and functional consequences.

Authors:  Christian Cornelissen; Juliane Lüscher-Firzlaff; Jens Malte Baron; Bernhard Lüscher
Journal:  Eur J Cell Biol       Date:  2011-10-05       Impact factor: 4.492

4.  IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis.

Authors:  Ulrike Raap; Sigo Weißmantel; Manuela Gehring; Anna M Eisenberg; Alexander Kapp; Regina Fölster-Holst
Journal:  Pediatr Allergy Immunol       Date:  2012-05       Impact factor: 6.377

5.  Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells.

Authors:  C Cornelissen; R Brans; K Czaja; C Skazik; Y Marquardt; G Zwadlo-Klarwasser; A Kim; D R Bickers; J Lüscher-Firzlaff; B Lüscher; J M Baron
Journal:  Br J Dermatol       Date:  2011-10-17       Impact factor: 9.302

6.  Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis.

Authors:  Mark M Neis; Bettina Peters; Alexandra Dreuw; Joerg Wenzel; Thomas Bieber; Cornelia Mauch; Thomas Krieg; Sven Stanzel; Peter C Heinrich; Hans F Merk; Andreas Bosio; Jens M Baron; Heike M Hermanns
Journal:  J Allergy Clin Immunol       Date:  2006-09-01       Impact factor: 10.793

Review 7.  Eosinophils and atopic dermatitis.

Authors:  D Simon; L R Braathen; H-U Simon
Journal:  Allergy       Date:  2004-06       Impact factor: 13.146

Review 8.  Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology.

Authors:  Josiane S Neves; Peter F Weller
Journal:  Curr Opin Immunol       Date:  2009-08-24       Impact factor: 7.486

9.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.

Authors:  Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross
Journal:  Nat Immunol       Date:  2004-06-06       Impact factor: 25.606

10.  Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation.

Authors:  Bryony Stott; Paul Lavender; Sarah Lehmann; Davide Pennino; Stephen Durham; Carsten B Schmidt-Weber
Journal:  J Allergy Clin Immunol       Date:  2013-05-18       Impact factor: 10.793
View more
  23 in total

Review 1.  [Update on the cutaneous neurobiology of pruritus].

Authors:  U Raap; E Papakonstantinou; M Metz; U Lippert; M Schmelz
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

Review 2.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

Review 3.  Atopic dermatitis: molecular, cellular, and clinical aspects.

Authors:  Jafar Salimian; Zahra Salehi; Ali Ahmadi; Alireza Emamvirdizadeh; Seyyed Masoud Davoudi; Mehrdad Karimi; Mohsen Korani; Sadegh Azimzadeh Jamalkandi
Journal:  Mol Biol Rep       Date:  2022-01-06       Impact factor: 2.316

Review 4.  [Neurophysiology of atopic pruritus].

Authors:  N H Meyer; B Gibbs; M Schmelz; B Homey; U Raap
Journal:  Hautarzt       Date:  2018-03       Impact factor: 0.751

5.  Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment.

Authors:  Alain H Rook; Kathryn A Rook; Daniel J Lewis
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  New and Emerging Therapies for Pediatric Atopic Dermatitis.

Authors:  Henry L Nguyen; Katelyn R Anderson; Megha M Tollefson
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

Review 7.  Eosinophils in skin diseases.

Authors:  Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623

Review 8.  The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis.

Authors:  Lai-San Wong; Yu-Ta Yen; Chih-Hung Lee
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

9.  Patterns among Patients with Chronic Pruritus: A Retrospective Analysis of 170 Patients.

Authors:  Mathias Lehmann; Simone Cazzaniga; Dagmar Simon; Delphine L. Perruchoud; Luca Borradori; Anna Rammlmair
Journal:  Acta Derm Venereol       Date:  2020-02-29       Impact factor: 3.875

10.  Role of Eosinophil Relative Count and Neutrophil-to-Lymphocyte Ratio in the Assessment of Severity of Atopic Dermatitis.

Authors:  Sanae Inokuchi-Sakata; Yozo Ishiuji; Michie Katsuta; Budiman Kharma; Ken-Ichi Yasuda; Mitsutoshi Tominaga; Kenji Takamori; Yoshimasa Nobeyama; Akihiko Asahina
Journal:  Acta Derm Venereol       Date:  2021-07-07       Impact factor: 3.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.